Infantile toxic epidermal necrolysis: Successful treatment of an 8-week-old with intravenous immunoglobulin and amniotic membrane transplant

Janelle S Nassim; Sabrina A Karim; Pierre-Olivier Grenier; Birgitta Schmidt; Krystal M Jones

doi:10.1111/pde.14376

Infantile toxic epidermal necrolysis: Successful treatment of an 8-week-old with intravenous immunoglobulin and amniotic membrane transplant

Pediatr Dermatol. 2021 Jan;38(1):202-205. doi: 10.1111/pde.14376. Epub 2020 Oct 30.

Authors

Janelle S Nassim^{1

2}, Sabrina A Karim^{2

3}, Pierre-Olivier Grenier^{1

2}, Birgitta Schmidt^{1

4}, Krystal M Jones^{1

2}

Affiliations

¹ Dermatology Program, Boston Children's Hospital, Boston, Massachusetts.
² Harvard Medical School, Boston, Massachusetts.
³ Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts.
⁴ Department of Pathology, Boston Children's Hospital, Boston, Massachusetts.

PMID: 33125180
DOI: 10.1111/pde.14376

Abstract

Stevens-Johnson syndrome and toxic epidermal necrolysis comprise a spectrum of severe mucocutaneous hypersensitivity reactions. A paucity of data limits current understanding of the etiology, treatment options, and prognosis of this entity in the infantile population compared to that in the adult and pediatric literature. We describe the case of an 8-week-old male with toxic epidermal necrolysis treated successfully with intravenous immunoglobulin and amniotic membrane transplant. This patient is the youngest surviving infant with toxic epidermal necrolysis to be reported.

Keywords: drug reaction; mucous membrane disorders; neonatal; therapysystemic.

Publication types

Case Reports

MeSH terms

Adult
Amnion
Child
Humans
Immunoglobulins, Intravenous / therapeutic use
Infant
Male
Stevens-Johnson Syndrome* / diagnosis
Stevens-Johnson Syndrome* / drug therapy
Stevens-Johnson Syndrome* / etiology

Substances

Immunoglobulins, Intravenous